Verastem (VSTM) Stock Rockets on Data Publication

Verastem Oncology VSTM Stock News

Verastem Inc (NASDAQ: VSTM) is making a move for the top in the market this morning, and for good reason. The company announced a data publication surrounding one of its candidates. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VSTM Stock Pops on Data Publication News

In the press release, Verastem said that new data hae been published  in The Lancet Oncology. The published data centered around a study that evaluated the intermittent dosing schedule of VS-6766. The goal was to provide information for further testing of the treatment both as a single agent in RAS-RAF-mutant cancers or in combination with small molecules.

VSTM went on to say that in the dose-escalation study, tolerability and antitumor activity were observed across various cancers with RAS/RAF/MEK pathway mutations.  To read the full publication, click here.

In a statement, Brian Stuglik, CEO at VSTM, had the following to offer:

These results support the potential of VS-6766 as a treatment for a variety of cancers where conventional approaches have been sub-optimal and there is significant unmet need. We believe VS-6766 has the potential to be the backbone of RAS therapy by addressing the multiple points of resistance and toxicity issues that have made advancing new options difficult.

Our Phase 2 registration-directed trials with VS-6766 in low grade serous ovarian cancer and KRAS mutant NSCLC are scheduled to begin by the end of this year. These adaptive design trials are a capital efficient approach to rapidly evaluate VS-6766 alone or in combination with defactinib to determine which regimen to take forward into the expansion phase of the trial.

This Is Big News

The news released by Verastem proved to be overwhelmingly positive. Ultimately, in the dose escallation study, VS-6766 has proven to be well-tolerated among patients with varying forms of cancer. Perhaps more importantly, the treatment is showing strong signs of efficacy in early development.

Should all continue to go well with VS-6766, VSTM could be sitting on a blockbuster. After all, the treatment is being developed to address various types of cancer with various mutations. If the drug saw approval in just one of these cancer indications, it would have strong potential, but with such a vast target, there’s a massive opportunity here. All in all, with the positive early data released this morning, VSTM stock is one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don't Miss the Next Big Story

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.